Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SAN FRANCISCO, April 05, 2018 -- Hagens Berman Sobol Shapiro LLP alerts investors in Solid Biosciences, Inc. (NASDAQ:SLDB) to the May 29, 2018 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the District of Massachusetts. If you purchased Solid Biosciences securities pursuant and/or traceable to its January 25, 2018 initial public offering and/or on the open market between January 25, 2018 and March 14, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information, visit:
https://www.hbsslaw.com/cases/SLDB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
Defendants conducted an initial public offering of Solid Biosciences on or about January 25, 2018. In this IPO, the Company sold approximately 7 million shares at $16 per share to investors.
On March 15, 2018, Defendants announced the U.S. Food and Drug Administration placed a clinical hold on the Company’s Phase 1/2 trial assessing its SGT-001 drug in patients with Duchenne muscular dystrophy. This news drove the price of Solid Biosciences shares down $16.99, or about 65%, to close at $9.32.
The Motley Fool later reported that just prior to the IPO, a prominent researcher left its board because of risks associated with the drug delivery method for Solid Biosciences’ SGT-001 drug.
“We’re focused on investors’ losses and Defendants’ disclosures about internal concerns over the safety of the SGT-001 delivery method leading up to- and after- the IPO,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Solid Biosciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
